Mechanisms of Ascorbate-Induced Cytotoxicity in Pancreatic Cancer
Open Access
- 14 January 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 16 (2), 509-520
- https://doi.org/10.1158/1078-0432.ccr-09-1713
Abstract
Purpose: Pharmacologic concentrations of ascorbate may be effective in cancer therapeutics. We hypothesized that ascorbate concentrations achievable with i.v. dosing would be cytotoxic in pancreatic cancer for which the 5-year survival is Experimental Design: Pancreatic cancer cell lines were treated with ascorbate (0, 5, or 10 mmol/L) for 1 hour, then viability and clonogenic survival were determined. Pancreatic tumor cells were delivered s.c. into the flank region of nude mice and allowed to grow at which time they were randomized to receive either ascorbate (4 g/kg) or osmotically equivalent saline (1 mol/L) i.p. for 2 weeks. Results: There was a time- and dose-dependent increase in measured H2O2 production with increased concentrations of ascorbate. Ascorbate decreased viability in all pancreatic cancer cell lines but had no effect on an immortalized pancreatic ductal epithelial cell line. Ascorbate decreased clonogenic survival of the pancreatic cancer cell lines, which was reversed by treatment of cells with scavengers of H2O2. Treatment with ascorbate induced a caspase-independent cell death that was associated with autophagy. In vivo, treatment with ascorbate inhibited tumor growth and prolonged survival. Conclusions: These results show that pharmacologic doses of ascorbate, easily achievable in humans, may have potential for therapy in pancreatic cancer. Clin Cancer Res; 16(2); 509–20Other Versions
This publication has 46 references indexed in Scilit:
- Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effectsFree Radical Biology & Medicine, 2009
- Mitochondrial DNA Depletion Induces Radioresistance by Suppressing G2Checkpoint Activation in Human Pancreatic Cancer CellsRadiation Research, 2009
- Phase I clinical trial of i.v. ascorbic acid in advanced malignancyAnnals of Oncology, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Tumor Suppressor 101F6 and Ascorbate Synergistically and Selectively Inhibit Non–Small Cell Lung Cancer Growth by Caspase-Independent Apoptosis and AutophagyCancer Research, 2007
- Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivoProceedings of the National Academy of Sciences of the United States of America, 2007
- In vitro Modeling of Human Pancreatic Duct Epithelial Cell Transformation Defines Gene Expression Changes Induced by K-ras Oncogenic Activation in Pancreatic CarcinogenesisCancer Research, 2005
- High-Dose Vitamin C versus Placebo in the Treatment of Patients with Advanced Cancer Who Have Had No Prior ChemotherapyThe New England Journal of Medicine, 1985
- Failure of High-Dose Vitamin C (Ascorbic Acid) Therapy to Benefit Patients with Advanced CancerThe New England Journal of Medicine, 1979
- The orthomolecular treatment of cancer II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancerChemico-Biological Interactions, 1974